Internal Medicine, Pulmonary Disease · Dallas, TX
NPI
1497816862
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
3410 Worth St, Suite 250
Dallas, TX, 75246
Phone (802) 820-6856
Groups this clinician bills Medicare through
Medicare paid, 2024
$35K
1,049 services
Medicare patients, 2024
169
Average age 73
Drug cost, 2024
$3.2M
2,042 prescriptions
Company payments, 2025
$55K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yolanda N Mageto was code 94729 (pulmonary function testing), 228 times for 138 patients. In total Yolanda N Mageto billed 1,049 services in 18 codes, and Medicare paid $35K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-06-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94729 Pulmonary Function Testing | Facility | 228 | 138 | $6.69 | $1,524 |
| 94010 Pulmonary Function Testing | Facility | 223 | 133 | $6.17 | $1,376 |
| 94618 Pulmonary Function Testing | Facility | 220 | 135 | $16.74 | $3,683 |
| 99214 Office E&M - Established | Facility | 191 | 118 | $74.47 | $14K |
| 99215 Office E&M - Established | Facility | 76 | 58 | $104.75 | $7,961 |
| 99213 Office E&M - Established | Facility | 33 | 29 | $49.54 | $1,635 |
| 94726 Pulmonary Function Testing | Facility | 18 | 18 | $9.02 | $162 |
| 94060 Pulmonary Function Testing | Facility | 17 | 17 | $7.79 | $132 |
| 99205 Office E&M - New | Facility | 15 | 15 | $140.78 | $2,112 |
By year: 2022 $20K for 317 services; 2023 $27K for 818 services; 2024 $35K for 1,049 services.
Medicare prescription drug claims, 2024
In 2024, the drug Yolanda N Mageto prescribed most often to Medicare patients was Prednisone, with 316 prescriptions and refills. In total Yolanda N Mageto wrote 2,042 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 316 | 601 | 100 | $1,920 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 188 | 256 | 38 | $160K |
| Mycophenolate Mofetil Generic | 126 | 241 | 26 | $15K |
| Ofev Nintedanib Esylate | 112 | 112 | 21 | $1.5M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 104 | 225 | 25 | $794 |
| Methotrexate Methotrexate Sodium | 99 | 144 | 17 | $970 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 97 | 117 | 38 | $3,135 |
| Pirfenidone Generic | 88 | 88 | 11 | $295K |
| Mycophenolic Acid Mycophenolate Sodium | 70 | 104 | 16 | $9,979 |
| Breo Ellipta Fluticasone/Vilanterol | 67 | 90 | 17 | $35K |
| Omeprazole Generic | 46 | 128 | 18 | $1,053 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 38 | 56 | Under 11 | $7,020 |
| Methylprednisolone Generic | 38 | 40 | 26 | $1,139 |
| Tyvaso Dpi Treprostinil | 36 | 37 | Under 11 | $867K |
| Metoprolol Tartrate Generic | 33 | 64 | Under 11 | $112 |
Brand drugs: - claims; generic drugs: 1,339 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Yolanda N Mageto $55K ($53K in general payments such as food, travel and fees and $1,960 for research) from 13 companies. The largest payer was United Therapeutics Corporation with $22K.
| Company | Payments | Amount |
|---|---|---|
| United Therapeutics Corporation UTHR | 22 | $22K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 22 | $15K |
| ANI Pharmaceuticals, Inc. ANIP | 17 | $15K |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $1,925 |
| Insmed, Inc. INSM | 7 | $172 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $76.53 |
| Grifols USA, LLC | 3 | $72.08 |
| GlaxoSmithKline, LLC. GSK | 4 | $70.7 |
| Genzyme Corporation SNY | 2 | $66.29 |
| Vifor Pharma, Inc. | 1 | $29.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.